
Ligand Pharmaceuticals Incorporated LGND
$ 195.64
1.38%
Quarterly report 2025-Q3
added 11-07-2025
Ligand Pharmaceuticals Incorporated Total Current Liabilities 2011-2026 | LGND
Annual Total Current Liabilities Ligand Pharmaceuticals Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.1 M | 16.8 M | 98.8 M | 41.7 M | 100 M | 17 M | 82.2 M | 239 M | 227 M | 223 M | 22.8 M | 28.9 M | 35.4 M | 43.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 239 M | 16.8 M | 86.7 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adagene
ADAG
|
38.2 M | $ 1.9 | -3.11 % | $ 107 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
174 M | $ 25.87 | -0.79 % | $ 1.25 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
4.46 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
13.1 M | - | - | $ 269 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.71 | 1.88 % | $ 17 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 64.74 | 1.41 % | $ 8.66 B | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 3.96 | -1.0 % | $ 8.62 B | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
5.53 B | $ 164.87 | 0.27 % | $ 24 B | ||
|
Bio-Path Holdings
BPTH
|
1.91 M | - | - | $ 100 K | ||
|
BioVie
BIVI
|
2.27 M | $ 1.23 | 2.07 % | $ 1.82 M | ||
|
Baudax Bio
BXRX
|
21.5 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M |